The optimal duration of neoadjuvant radiotherapy in rectal cancer remains controversial. This is a multi-center retrospective cohort study. Appropriate preoperative selection of radiotherapy duration was not associated with survival differences. Background: The utility of neoadjuvant radiotherapy (nRT) for the treatment of stage II and III rectal cancer is wellestablished. However, the optimal duration of nRT in this setting remains controversial. Using a population-based cohort of patients with stage II and III rectal cancer (RC) treated with curative intent, our aims were to (1) examine the patterns of nRT use and (2) explore the relationship between different nRT schedules and survival in the real-world setting. Methods: This is a multi-center retrospective cohort study based on population-based data from 5 regional comprehensive cancer centers in British Columbia, Canada. We analyzed patients diagnosed with clinical stage II or III RC from 2006 to 2010 and treated with either short-course (SC) or long-course (LC) nRT prior to curative intent surgery. Logistic regression models were constructed to determine the factors associated with the course of nRT delivered to patients. Kaplan-Meier methods and Cox regression that accounted for known prognostic factors were used to evaluate the relationship between nRT schedule and overall (OS), disease-free (DFS), local recurrence-free (LRFS), and distant recurrence-free survival (DRFS). Results: We identified 427 patients: the median age was 65 years (range, 31 to 94 years), 67% were men, 87% had T3 or T4 tumors, and 74% had N1 or N2 disease. Among them, 241 (56%) received SC and 186 (44%) received LC. Adjusting for confounders, patients with N1 or N2 disease were more likely to undergo LC (odds ratio [OR], 5.08; 95% confidence interval [CI], 2.51-11.22; P < .0001 and OR, 8.35; 95% CI, 3.35-22.39; P < .0001, respectively), whereas older age patients were less likely to receive LC (OR, 0.95; 95% CI, 0.94-0.98; P < .0001). In Kaplan-Meier analysis, there were no significant differences observed in OS, DFS, LRFS, and DRFS between SC and LC. Likewise, multivariate analyses demonstrated that OS (hazard ratio [HR], 0.91; 95% CI, 0.61-1.37; P ¼ .66), DFS (HR, 1.06; 95% CI, 0.68-1.64; P ¼ .80), LRFS (HR, 0.79; 95% CI, 0.39-1.57; P ¼ .50) and DRFS (HR, 0.99; 95% CI, 0.60-1.61; P ¼ .95) were similar regardless of nRT schedules. Additional baseline clinical and tumor characteristics did not influence outcomes (all P > .05). Conclusion: Appropriate preoperative selection of SC versus LC nRT for locally advanced RC based on patient and tumor characteristics was not associated with differences in survival outcomes in the real-world setting.
Introduction
Despite advances in screening, diagnosis, and treatment in recent decades, colorectal cancer continues to be a global health problem and currently represents the third most common cancer among men and the second most common cancer among women. 1 Anatomically, rectal cancer refers to disease affecting the portion of the large bowel ending at the pectinate line and extending upwards for about 15 cm. 2 In 2016, there was an estimated 39,220 newly diagnosed rectal cancer cases in the United States alone. 3 Compared with colon cancer, malignancies of the rectum are more challenging to manage and also associated with a worse prognosis based on stage.
The management approach for rectal cancer is frequently complex and multi-disciplinary. Treatment decisions are based on a number of patient-and tumor-related factors, 4 such as age and comorbidities, 5 as well as tumor stage, anatomical subsite, and other biological characteristics. For patients with clinical stage I disease (T1-2, N0), surgery alone is considered the accepted standard of care. Conversely for patients with clinical stage II or III disease (T3-4 and/or N1-2), neoadjuvant therapy in addition to surgery followed by adjuvant treatment is considered the most appropriate treatment strategy. Specifically, the neoadjuvant component incorporates the use of preoperative radiotherapy with or without concurrent chemotherapy. There are variations in the schedule of neoadjuvant radiotherapy (nRT), with 2 approaches that are most commonly used: (1) preoperative short-course (SC) radiotherapy consisting of 25 Gy in 5 fractions without chemotherapy or (2) preoperative long-course (LC) radiotherapy (45-50. 4 Gy in 25-28 fractions) delivered concurrently with fluoropyrimdine (eg, capecitabine or infusional 5-fluorouracil) chemotherapy. 6 These 2 neoadjuvant treatment schedules have been compared with surgery alone or surgery followed by adjuvant (chemo) radiotherapy with outcomes consistently supporting the use of 1 of these neoadjuvant approaches. [7] [8] [9] [10] There have also been some comparisons between the 2 nRT schedules, 11-13 but a robust real-world evaluation of the 2 regimens are lacking. In Europe, SC nRT is most commonly prescribed, whereas LC nRT combined with chemotherapy is favored in the United States. 14 Therefore, the main objectives of the current population-based study are to describe the impact of SC versus LC nRT on the survival outcomes of patients with rectal cancer in the real world setting and to evaluate the impact of additional clinical and pathologic factors on survival outcomes stratified by nRT schedule.
Methods

General Overview of the Study Setting
The British Columbia Cancer Agency (BCCA) is a provincial cancer control program that is responsible for providing cancer management to approximately 4.5 million residents in the province. At the time of this analysis, BCCA was comprised of 5 geographically distributed cancer centers to ensure equitable access to cancer care regardless of place of residence. All of these centers provide a full range of cancer control services, including outpatient clinics, chemotherapy suites, radiotherapy facilities, surgical oncology services, inpatient units, and palliative and supportive care, as well as the opportunity to participate in cancer clinical trials.
Gastrointestinal Cancers Outcomes Unit
The Gastrointestinal Cancers Outcomes Unit (GICOU) database is a provincial data repository that prospectively collates demographic, disease, treatment, and outcome data for patients with gastrointestinal cancers who reside in the province at the time of their diagnosis and who are referred to any 1 of the 5 BCCA centers for their management. Various baseline factors are available, including age, gender, Eastern Cooperative Oncology Group (ECOG) performance score, anatomical site and histopathology of the tumor, date and type of surgery performed, clinical and pathologic tumor stage at the time of diagnosis, extent of nodal sampling and retrieval, details of systemic therapy/radiotherapy received, and date of recurrence and death.
Selection of the Study Cohort
Medical information from the GICOU database of patients with rectal cancer with clinical stage II or III disease who were treated between January 2006 and December 2010 were extracted and reviewed. Eligible cases included individuals who were treated preoperatively with either SC radiotherapy (25 Gy in 5 fractions) or LC chemo-radiotherapy (45-50.4 Gy in conventional fractionations) followed by radical curative intent surgery. Patients were excluded from analyses if they had a tumor histology other than adenocarcinoma. Review of individual medical records was conducted if data were missing from the GICOU data repository. Appropriate ethical committee approvals were obtained from each of the 5 centers prior to the conduct of this study.
Data Collection
The following data parameters were abstracted for each eligible case: age at diagnosis, gender, ECOG status, pretreatment clinical stage, pretreatment staging method, type of surgery, time between radiotherapy and surgery, operative pathology, postsurgical complications (if any), and adjuvant chemotherapy details, if available.
Statistical Analysis
Baseline characteristics were summarized with descriptive statistics. c 2 tests were used to compare clinicopathologic characteristics and treatment outcomes between the 2 nRT schedules (SC vs. LC). Logistic regression models expressed as hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were additionally constructed to determine the clinical factors associated with the course of nRT delivery. Kaplan-Meier analysis and log-rank tests were used to assess for outcome differences, including overall (OS), disease-free (DFS), local recurrence-free (LRFS), and distant recurrence-free survival (DRFS). Cox proportional models were built to identify prognostic factors that impacted OS and DFS as measured by HRs and corresponding 95% CIs. All tests were 2-sided where a P-value of < .05 was considered statistically significant. All statistical analyses were conducted using SPSS Statistics 20.0.
Results
Cohort Characteristics
A total of 427 patients with rectal cancer were identified and included in the current analysis. Among them, 241 (56%) received preoperative SC radiotherapy and 186 (44%) received preoperative LC chemo-radiotherapy. postoperative characteristics of these patients. The median age of the overall cohort was 65 years (range, 31-94 years), 67% of patients were men, 87% had T3 or T4 tumors, and 74% had clinically node-positive disease. Preoperative assessment was conducted through computerized tomography (CT) in 98% of cases in addition to endo/trans-rectal ultrasound (US) in 32% of cases and abdominal/pelvic magnetic resonance imaging in 46% of cases. Differences in baseline characteristic were noted between the SC and LC nRT groups, respectively, in terms of preoperative T stage (0.8% vs. 16.1% with T4 disease), N stage (19.5% vs. 5.4% with node-negative disease), and performance status (44.8% vs. 65.1% with ECOG 0/1) (all P < .0001). Additional differences were also observed among patients who underwent SC and LC nRT with respect to type of surgery (73.5% vs. 52.0% sphincter-preserving surgery [low anterior resection]), use of adjuvant chemotherapy (49.8% vs. 71.0%), and rate of pathologic complete response (ypT0N0) (0% vs. 12.9%) (all P < .0001). No variations were seen between groups with regards to postoperative complications. The median time between completion of radiotherapy and receipt of surgery was 1.5 weeks and 5.6 weeks in the SC and LC groups, respectively. Concurrent and adjuvant chemotherapy use was largely fluoropyrimidine-based. None of the patients in the study cohort were treated with induction chemotherapy prior to neoadjuvant (chemo) radiotherapy. Radiotherapy was planned and delivered through the 3-dimensional conformal radiotherapy technique. In the long-course group, additional radiotherapy boost was delivered in 52% (97 patients) of the cases. Planning and delivery of the radiotherapy was at the discretion of the treating physician and according to the guidelines of each institution. Adjusting for measured confounders in logistic regression models, patients with N1 and N2 disease were more likely to receive LC nRT (odds ratio [OR], 5.08; 95% CI, 2.51-11.22; P < .0001 and OR, 8.35; 95% CI, 3.35-22.39; P < .0001, respectively), whereas older age patients were less likely to receive LC nRT (OR, 0.95; 95% CI, 0.94-0.98; P < .0001).
Survival Outcomes
In univariate analyses, there were no significant differences seen in OS, DFS, LRFS, and DRFS between LC and SC nRT ( Figure 1A-D ). An additional Kaplan-Meier assessment for the impact of pathologic complete response on outcomes in the entire study cohort revealed a significant correlation between attainment of pathologic complete response and better overall survival (P < .0001) (Figure 2 ). In Cox proportional hazard models (Table 2) , LC versus SC was not associated with differences in OS (HR, 0.91; 95% CI, 0.61-1.37; P ¼ .66), DFS (HR, 1.06; 95% CI, 0.68-1.64; P ¼ .80), LRFS (HR, 0.79; 95% CI, 0.39-1.57; P ¼ .50), and DRFS (HR, 0.99; 95% CI, 0.60-1.61; P ¼ .95). Except for the impact of age on OS (HR, 1.04; 95% CI, 1.03-1.06; P < .0001), additional baseline clinical and tumor characteristics did not influence outcomes (all P > .05). 
Discussion
The current study demonstrates that appropriate preoperative selection of SC radiotherapy versus LC neoadjuvant chemoradiotherapy for stage II or III rectal cancer based on patient and tumor characteristics was not associated with differences in survival outcomes. Moreover, patients attaining pathologic complete response have much better survival outcomes compared with those not attaining pathologic complete response.
In particular, we observed that LC treatment was more likely to be given to younger patients with better performance status as well as those with more advanced disease. This is expected given the better tolerability of younger patients to a more protracted course of treatment and previous data suggesting better operative results of longer treatment among patients with more locally advanced disease. Pretreatment radiologic assessment modalities in the current study included pelvic CT, magnetic resonance imaging, and rectal ultrasound. A number of prior studies have confirmed the important role played by proper pretreatment radiologic assessment in guiding proper decision-making as well as the correlation between radiologic findings and overall outcomes of patients with rectal cancer. 15, 16 Despite the fact that there was no apparent difference in survival outcomes between neoadjuvant LC chemo/radiation and SC radiotherapy, LC was more likely to be associated with pathologic complete response in the current study. These findings are in line with a previously published Cochrane review. 17 In turn, complete pathologic response was associated with better OS in the current analysis; this is also consistent with previously published studies demonstrating improved outcomes with complete pathologic response. [18] [19] [20] Although pathologic complete response occurred exclusively in patients receiving LC therapy in our study, this did not consistently translate to better overall outcomes for the LC group. One potential explanation for this observation is that there were clear differences in baseline characteristics based on treatment, whereby patients with more advanced disease were also more likely to receive LC therapy. This may have offset the positive effects that may have otherwise been expected in the LC subset. Likewise, the rate of sphincter-preserving surgery (low anterior resection) was higher among patients treated with SC radiotherapy. This was also most likely attributed to the fact that there were more locally advanced patients who underwent LC treatment, highlighting that sphincter preservation differences were likely secondary to variations in baseline characteristics rather than a therapeutic effect from the different neoadjuvant protocols. Indeed, previous randomized reports also failed to show a difference in sphincter preservation between neoadjuvant approaches. 12, 13 Median duration between end of radiation therapy and surgery was 1.5 weeks in the SC group, whereas it was 5.6 weeks in the LC group. This is comparable with the protocols of the landmark studies. 7, 10 More recent studies have suggested that increasing the duration between radiation therapy and surgery may increase the rate of pathologic complete response (from 1.7% to 11.8%), Figure 1 Kaplan-Meier Survival Analysis for the Impact of the Type of Neoadjuvant Treatment (Long Course Chemo-radiotherapy vs. Short-course Radiotherapy) on Overall Survival (A); Disease-free Survival (B); Local Relapse-free Survival (C); and Distantrelapse Free Survival (D)
Abbreviation: RT ¼ radiotherapy.
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suggesting that the pathologic complete response observed with the LC protocol is actually a function of increasing the duration between radiation therapy and surgery rather than a direct therapeutic effect of the LC treatment. 21 This hypothesis has been controversial, especially because longer intervals between radiation and surgery might be associated with increased risk of complications.
22
Both infusional 5-fluorouracil and capecitabine were used as concurrent chemotherapy in our study. Previous data have shown equivalent performance of either agent in rectal cancer 23 and treatment selection rests at the discretion of the treating physician. Numerous studies have also evaluated the potential benefit of adding oxaliplatin to concurrent fluoropyrimidine in the 
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e26 -Clinical Colorectal Cancer March 2018 neoadjuvant setting; however, there is no clear demonstrable benefit for this approach in the majority of these studies to date. 24, 25 Radiotherapy was planned and delivered in the current study through CT-based 3-dimensional conformal radiotherapy with boost being delivered in almost one-half of the patients receiving LC treatment. The role of radiotherapy boost has been debated, given the additional acute toxicities reported in prior retrospective and prospective studies of this approach. [26] [27] [28] Moreover, some encouraging dosimetric results have highlighted the potential role of positron emission tomography/CT-based planning approaches in neoadjuvant radiotherapy for rectal cancer. 29 The clinical impact of such approaches is yet to be shown prospectively. 30 Several limitations should be considered when interpreting the results of this study. First, a number of relevant baseline characteristics were imbalanced between the 2 study groups. Although we conducted a multivariate analysis that adjusted for measured confounders, residual confounding owing to unmeasured factors remains. Second, the size of our cohort is relatively small, so it may have been underpowered to detect minor survival differences between nRT groups. Nonetheless, this should be balanced by the fact that this represented a population-based sample across 5 cancer centers in 1 province so findings are generalizable and reflective of the real world. Finally, the retrospective nature of the study design means that there is inherent selection bias, so we cannot infer causation. Rather, our results suggest that both SC and LC nRT appear safe and offer comparable effectiveness when their use is properly selected according to patient and tumor characteristics.
In conclusion, SC preoperative radiotherapy versus LC neoadjuvant chemo-radiotherapy for stage II to III rectal cancer when used in carefully selected patient populations do not seem to affect survival outcomes in the real-world setting. Studies that examine the roles of induction chemotherapy prior to neoadjuvant (chemo) radiotherapy, newer targeted and immunotherapeutic strategies that offer improved local and systemic control, and expectant management and active surveillance in complete responders following neoadjuvant treatment should be the focus of the future because they may further enhance the benefits derived from our current paradigm of nRT in rectal cancer.
Clinical Practice Points
The utility of nRT for the treatment of stage II and III rectal cancer is well-established. However, the optimal duration of nRT in this setting remains controversial. This is a multi-center retrospective cohort study based on population-based data from 5 regional comprehensive cancer centers in British Columbia, Canada. We analyzed patients diagnosed with clinical stage II or III rectal cancer from 2006 to 2010 and treated with either SC or LC nRT prior to curative intent surgery. We identified 427 patients: the median age was 65 years (range, 31 to 94 years), 67% were men, 87% had T3 or T4 tumors, and 74% had N1 or N2 disease. Adjusting for confounders, patients with N1 or N2 disease were more likely to undergo LC (OR, 5.08; 95% CI, 2.51-11.22; P < .0001 and OR, 8.35; 95% CI, 3.35-22.39; P < .0001, respectively), whereas older age patients were less likely to receive LC (OR, 0.95; 95% CI, 0.94-0.98; P < .0001). In Kaplan-Meier analysis, there were no significant differences observed in OS, DFS, LRFS, and DRFS between SC and LC nRT. Likewise, multivariate analyses demonstrated that OS (HR, 0.91; 95% CI, 0.61-1.37; P ¼ .66), DFS (HR, 1.06; 95% CI, 0.68-1.64; P ¼ .80), LRFS (HR, 0.79; 95% CI, 0.39-1.57; P ¼ .50), and DRFS (HR, 0.99; 95% CI, 0.60-1.61; P ¼ .95) were similar regardless of nRT schedules. Additional baseline clinical and tumor characteristics did not influence outcomes (all P > .05).
